Announcements Trials
Browse Landscape

Phase

Phase 2 40Phase 1/2 20Phase 1 19Phase 3 5Phase EARLY_PHASE1 2Phase NA 1

Status

Completed 27Recruiting 12Active not recruiting 11Unknown 6Terminated 5Not yet recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Breast 1

Conditions

Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1NSCLC 1Carcinoma, Pancreatic Ductal 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 49Radiotherapy 47Docetaxel 42Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Imatinib Mesylate 14Drug Therapy 14Irinotecan 13Filgrastim 13Zoledronic Acid 12Trastuzumab 12Radiosurgery 12Erlotinib Hydrochloride 12Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Albumin-Bound Paclitaxel × Clear all
NCT04251533 2026-05-11

EPIK-B3

Novartis

Phase 3 Terminated
137 enrolled 21 charts
Breast

Triple Negative Breast Neoplasms

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

NCT04329949 2023-11-18

RELIANT

Corcept Therapeutics

Phase 3 Terminated
43 enrolled 17 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02715804 2020-07-14

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Halozyme Therapeutics

Phase 3 Terminated
492 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Carcinoma, Pancreatic Ductal

NCT01836432 2020-05-28

PILLAR

Lumos Pharma

Phase 3 Terminated
302 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡